{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:59:20Z","timestamp":1781193560090,"version":"3.54.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.clinthera.2026.02.001","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:05:06Z","timestamp":1773407106000},"page":"571-582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Fetal Transplacental Therapy to Mitigate Consequences of Cystic Fibrosis"],"prefix":"10.1016","volume":"48","author":[{"given":"Charissa W.","family":"Kam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron J.","family":"McKinzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6785-5076","authenticated-orcid":false,"given":"Jennifer L.","family":"Goralski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.02.001_bib0001","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1080\/14656566.2024.2426677","article-title":"Shifting sands in cystic fibrosis\u201d: impacts of CFTR modulators on reproductive health in people with cystic fibrosis and challenges related to in utero exposure","volume":"25","author":"Felton","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0002","first-page":"47","article-title":"Pregnancy in people with cystic fibrosis treated with highly effective modulator therapy","volume":"145","author":"Goralski","year":"2025","journal-title":"Obstet Gynecol"},{"issue":"12","key":"10.1016\/j.clinthera.2026.02.001_bib0003","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1002\/ppul.26706","article-title":"Use of CFTR modulators in special populations, part 1: pregnancy and lactation","volume":"58","author":"Elijah","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0004","series-title":"2024 Cystic Fibrosis Foundation Patient Registry Highlights","year":"2025"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jcf.2024.12.003","article-title":"Learning from the CFTR modulator baby boom","volume":"24","author":"Jain","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0006","unstructured":"Vertex Pharmaceuticals Incorporated. (2025). Kalydeco. Package insert. Boston, Mass."},{"key":"10.1016\/j.clinthera.2026.02.001_bib0007","unstructured":"Vertex Pharmaceuticals Incorporated. (2024). Trikafta. Package insert. Boston, Mass."},{"key":"10.1016\/j.clinthera.2026.02.001_bib0008","unstructured":"Vertex Pharmaceuticals Incorporated. Alyftrek. Package Insert. (2025). Boston, Mass."},{"key":"10.1016\/j.clinthera.2026.02.001_bib0009","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jcf.2021.03.018","article-title":"Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy","volume":"20","author":"Fortner","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0010","article-title":"Maternal, newborn and breast milk concentrations of elexacaftor\/tezacaftor\/ivacaftor in a F508del heterozygous woman with cystic fibrosis following successful pregnancy","volume":"7","author":"Ripani","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0011","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jcf.2021.12.004","article-title":"Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor","volume":"21","author":"Collins","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0012","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jcf.2021.07.019","article-title":"Pregnancy in cystic fibrosis: review of the literature and expert recommendations","volume":"21","author":"Jain","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.arcped.2025.03.005","article-title":"Preliminary proposals for the follow-up of infants born to mothers with cystic fibrosis treated with CFTR modulators during the first two years of life","author":"Reix","year":"2025","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107868","article-title":"Therapeutic drug monitoring of elexacaftor, tezacaftor, and ivacaftor before, during, and after pregnancy in women with cystic fibrosis: an observational study","volume":"236","author":"Shad","year":"2025","journal-title":"Respir Med"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0015","article-title":"Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design","volume":"9","author":"Jain","year":"2022","journal-title":"BMJ Open Respir Res"},{"issue":"1","key":"10.1016\/j.clinthera.2026.02.001_bib58","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jogn.2016.08.011","article-title":"A Case Report of Pregnancy During Use of Targeted Therapeutics for Cystic Fibrosis","volume":"46","author":"Ladores","year":"2017","journal-title":"J Obstet Gynecol Neonatal Nurs"},{"issue":"1","key":"10.1016\/j.clinthera.2026.02.001_bib61","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jcf.2015.11.013","article-title":"A successful uncomplicated CF pregnancy while remaining on Ivacaftor","volume":"15","author":"Kaminski","year":"2016","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0018","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jcf.2025.03.009","article-title":"First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: report from the MODUL-CF study","volume":"24","author":"Bonnel","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2025.07.013","article-title":"Elevated serum lipase in infants with cystic fibrosis exposed to prenatal and postnatal elexacaftor\/tezacaftor\/ivacaftor","author":"Haskett","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0044","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jcf.2022.10.004","article-title":"Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding","volume":"21","author":"Jain","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.clinthera.2026.02.001_bib59","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jcf.2024.09.025","article-title":"Elevated liver function tests in infants exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breastfeeding - Case reports","volume":"24","author":"Kolaczkowski","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0027","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.jcf.2024.06.003","article-title":"Clinical outcomes of two infants with cystic fibrosis, including presence of the vas deferens, born to a woman with cystic fibrosis taking CFTR modulators during both pregnancies","volume":"23","author":"Kowalik","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.clinthera.2026.02.001_bib60","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.therap.2022.01.020","article-title":"Pulmonary hemorrhage in a neonate born to a woman with cystic fibrosis treated with targeted cystic fibrosis transmembrane conductance regulator modulator elexacaftor-tezacaftor-ivaaftor during pregnancy","volume":"77","author":"Nuytten","year":"2022","journal-title":"Therapie"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0016","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/GCO.0000000000000346","article-title":"Maternal risks of fetal therapy","volume":"29","author":"Al-Refai","year":"2017","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2025.07.015","article-title":"PRenatal mOdulator treatment to PrEvent CF complicaTions (PROTECT) workshop report","author":"Szentpetery","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2024.101299","article-title":"The role of CFTR in the eye, and the effect of early highly effective modulator treatment for cystic fibrosis on eye health","volume":"103","author":"Schneider-Futschik","year":"2024","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116155","article-title":"Fetal drug exposure after maternally administered CFTR modulators Elexacaftor\/Tezacaftor\/Ivacaftor in a rat model","volume":"171","author":"Li","year":"2024","journal-title":"Biomed. Pharmacother"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0021","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1111\/bph.16417","article-title":"Extent of foetal exposure to maternal elexacaftor\/tezacaftor\/ivacaftor during pregnancy","volume":"181","author":"Li","year":"2024","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0028","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.71168","article-title":"Prenatal elexacaftor\/tezacaftor\/ivacaftor treatment prevents meconium ileus, but not exocrine pancreatic insufficiency and lung disease in infants with cystic fibrosis","volume":"60","author":"Aleksander","year":"2025","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0029","doi-asserted-by":"crossref","unstructured":"Blumenfeld Y, Hintz S, Aziz N, et al. Treatment of fetal cystic fibrosis with cystic fibrosis transmembrane conductance regulator modulation therapy. Ann Intern Med. 176, 1015\u20131016.","DOI":"10.7326\/L23-0112"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0031","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jcf.2025.03.006","article-title":"CFTR modulator therapy via carrier mother to treat meconium ileus in a F508del homozygous fetus: insights from an unsuccessful case","volume":"24","author":"Destoop","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0026","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000530261","article-title":"Prenatal cystic fibrosis transmembrane conductance regulator modulator therapy: a promising way to change the impact of cystic fibrosis","volume":"50","author":"G\u00f3mez-Montes","year":"2023","journal-title":"Fetal Diagn Ther"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0030","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jcf.2024.11.011","article-title":"Outcomes of prenatal use of elexacaftor\/tezacaftor\/ivacaftor in carrier mothers to treat meconium ileus in fetuses with cystic fibrosis","volume":"24","author":"Metcalf","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0025","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jcf.2022.04.005","article-title":"A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0022","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2021.03.006","article-title":"Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation","volume":"20","author":"Taylor-Cousar","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.clinthera.2026.02.001_bib0023","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jcf.2025.03.002","article-title":"CFTR modulators and pregnancy outcomes: early findings from a nationwide cohort study","volume":"24","author":"Chouchana","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2025.06.001","article-title":"Pregnancy and neonatal outcome following in utero exposure to CFTR modulators: a multicentre prospective case series","author":"Gautier","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0033","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jpedsurg.2008.10.010","article-title":"Neonatal outcomes associated with intestinal abnormalities diagnosed by fetal ultrasound","volume":"44","author":"Ruiz","year":"2009","journal-title":"J Pediatr Surg"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0034","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1002\/ppul.24353","article-title":"Time for a gut check: pancreatic sufficiency resulting from CFTR modulator use","volume":"54","author":"Megalaa","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0035","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jcf.2019.03.009","article-title":"An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2\u20135 years (KLIMB)","volume":"18","author":"Rosenfeld","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0036","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2\u20135 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study","volume":"4","author":"Davies","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0037","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcf.2022.10.003","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: report of promise-GI","volume":"22","author":"Schwarzenberg","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0038","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.71156","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on fecal elastase-1 in children with cystic fibrosis","volume":"60","author":"Sankararaman","year":"2025","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0039","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/ppul.25065","article-title":"Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftor","volume":"55","author":"Munce","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0040","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/ppul.24454","article-title":"Pancreatic insufficiency converted to pancreatic sufficiency with ivacaftor","volume":"54","author":"Hamilton","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0041","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01208-2019","article-title":"ERS\/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases","volume":"55","author":"Middleton","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0042","doi-asserted-by":"crossref","first-page":"eaau7531","DOI":"10.1126\/scitranslmed.aau7531","article-title":"In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis","volume":"11","author":"Sun","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0043","series-title":"The Early Bird Catches the \u2026 Sperm? Preserved Vas Deferens in CF","author":"Comadoll","year":"2025"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0045","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/13816810.2017.1301964","article-title":"Diagnosed cataracts in patients with cystic fibrosis in a United States administrative database","volume":"38","author":"Everage","year":"2017","journal-title":"Ophthalmic Genet"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0046","unstructured":"Tice JA, Kuntz KM, Wherry K, et al. (2020). Modulator treatments for cystic fibrosis: effectiveness and value. Institute for Clinical and Economic Review. https:\/\/icer.org\/wp-content\/uploads\/2020\/08\/ICER_CF_Final_Report_092320.pdf. Accessed July 23, 2025."},{"key":"10.1016\/j.clinthera.2026.02.001_bib0047","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.3705","article-title":"Predicting maternal and fetal exposures of elexacaftor-tezacaftor-ivacaftor during pregnancy through physiologically based pharmacokinetic models","author":"Hong","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0048","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jcf.2022.05.014","article-title":"Editorial\u2014the ethical implications of treating a pregnant woman to benefit the fetus","volume":"21","author":"Bennett","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0049","doi-asserted-by":"crossref","DOI":"10.1097\/GRF.0000000000000936","article-title":"Ethical considerations for maternal-fetal interventions: innovation, research, and oversight","author":"Anzabi","year":"2025","journal-title":"Clin Obstet. Gynecol"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0050","first-page":"208","article-title":"Ethically justified, practical guidance for the professionally responsible investigation of maternal-fetal intervention for fetal or neonatal benefit","volume":"3","author":"Chervenak","year":"2021","journal-title":"Mater-Fetal Med"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0051","unstructured":"Innovative Care Guidelines. (n.d.). https:\/\/stanfordhealthcare.org\/content\/dam\/SHC\/health-care-professionals\/medical-staff\/policies\/innovative-care-guidelines-final-3-18-11-copy.pdf. Accessed November 29, 2025."},{"key":"10.1016\/j.clinthera.2026.02.001_bib0052","unstructured":"Kalydeco | European Medicines Agency (EMA). (2017). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kalydeco. Accessed November 30, 2025."},{"key":"10.1016\/j.clinthera.2026.02.001_bib0053","unstructured":"Kaftrio | European Medicines Agency (EMA). (2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kaftrio. Accessed November 30, 2025."},{"key":"10.1016\/j.clinthera.2026.02.001_bib0054","unstructured":"Alyftrek | European Medicines Agency (EMA). (2025). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/alyftrek. Accessed November 30, 2025."},{"key":"10.1016\/j.clinthera.2026.02.001_bib0055","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262110513","article-title":"Real-world safety and effectiveness of elexacaftor, tezacaftor, and ivacaftor in people with cystic fibrosis and advanced lung disease: a two-year multicenter cohort study","volume":"26","author":"Volpi","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinthera.2026.02.001_bib0056","unstructured":"Cystic Fibrosis Canada. (n.d.). Recommendations for follow up of pregnancies and births on modulators. https:\/\/cysticfibrosis.ca\/resource\/recommendations-pregnancy-and-modulators Accessed July 23, 2025."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826000330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826000330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:17:23Z","timestamp":1781191043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826000330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0149291826000330"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.02.001","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fetal Transplacental Therapy to Mitigate Consequences of Cystic Fibrosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}